Antisoma to amend ACCEDE phase III study of AS1413
Hanmi's LAPS-GCSF got the US FDA's approval for clinical trials
YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
To keep up to date with news from this category use our
Vascular Solutions and Zerusa Limited Announce FDA Market Clearance for the Next Generation Guardian II Hemostasis Valve
MINNEAPOLIS, Minnesota and GALWAY, Ireland -October 12, 2009- Vascular Solutions, Inc. (Nasdaq:VASC) and Zerusa Limited today announced that they have received 510(k) clearance with the FDA for the sale of the Guardian
Antisoma to amend ACCEDE phase III study of AS1413
London, UK, and Cambridge, MA: 08 October 2009 Antisoma announces that, following discussions with FDA and trial investigators, it plans to amend the primary endpoint in the ACCEDE study of AS1413. The ACCEDE study is...
Phase 2 Study of KRX-0401 (Perifosine) in Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Open for Enrollment at Duke Comprehensive Cancer Center
NEW YORK, October 8, 2009 -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 2 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for relapsed or...
CML HealthCare Income Fund Provides Update on U.S. Medical Imaging Acquisition Activity
MISSISSAUGA, ON, Oct. 7 - CML HealthCare Income Fund (the "Fund" or "CML HealthCare"), (TSX: CLC.UN) today announced that its operating subsidiary, CML HealthCare Inc. ("CML") has entered into definitive agreements to...
YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
MISSISSAUGA, ON, Oct. 5, 2009 - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at...
Bayer's novel oral contraceptive Qlaira
Berlin, October 5, 2009 - Qlaira
Rockwell Medical Announces Closing of $22 Million Registered Direct Offering of Shares and Warrants
WIXOM, Mich. - October 5, 2009--Rockwell Medical Technologies, Inc. (Nasdaq: RMTI) a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic...
Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
RICHMOND, Calif., Oct 01, 2009 -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics,...
FDA Approves Additional Use for IUD Mirena to Treat Heavy Menstrual Bleeding in IUD Users
October 1, 2009 -- The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of...
New USP Standards for Heparin Products Will Result in Decreased Potency Adjustments may be needed to achieve desired anticoagulant effect in some patients New Heparin to Ship Starting October 8
October 1, 2009 -- The U.S. Food and Drug Administration today alerted health care professionals to a change in heparin manufacturing that is expected to decrease the potency of the common anti-clotting drug.
BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402
Lund, Sweden - 23 September 2009 - BioInvent International AB (OMXS) announces that it has started recruitment of the third and final cohort of 100 patients for the Phase II trial of TB-402, a drug being developed for...
Diagnostics HemoCue Subsidiary to Add U.S. Hospital Laboratory Connectivity to Its HemoCue 201 DM Point-of-Care Systems
MADISON, N.J., June 22, 2009 -- HemoCue Inc., the U.S. point-of-care testing distribution subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that it has signed an agreement with Medical Automation...
University of Southern California receives $1 million NIH grant to study TXA127 for the prevention of radiation damage
Brookline, MA, October 7,2008 -- Tarix Phamaceuticals today announced that the University of Southern California has received a grant to study the effects of TXA127 in preventing thrombocytopenia following radiation...
Tarix Pharmaceuticals receives FDA approval for Phase 2 study to mitigate chemotherapy-induced thrombocytopenia
Brookline,MA , June 25, 2008 -- Tarix Phamaceuticals announced that it has received FDA approval to begin a Phase II clinical trial of TXA127 for the prevention of chemotherapy induced thrombocytopenia. The trial will...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
